News

Eli Lilly to buy SiteOne for $1B
If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.
Indianapolis Business Journal1h
Lilly seeks to expand pain pipeline with $1B acquisition
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...
Stocktwits on MSN2h
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced
Eli Lilly and Company (LLY) said on Tuesday that it would acquire California-based private biotechnology company SiteOne ...
Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion
Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes SiteOne's STC-004, which is ...
Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...
InvestorsHub on MSN6h
Eli Lilly Expands Pain Treatment Pipeline with SiteOne Therapeutics Acquisition
Eli Lilly and Company (NYSE:LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued ...
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly
The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...